ADDRESS-2 is supporting a study to assess the safety of a new “type 1 diabetes vaccine” designed to stop the immune system from attacking insulin-producing beta cells.
Research study for people with Type 1 Diabetes: EXALT
The main purpose of this study is to assess the safety of three different doses of an investigational drug in patients who have been recently diagnosed with type 1 diabetes. The investigational drug is a “therapeutic vaccine” and affects the body’s immune system response to a medical condition or disease. It is designed to stop the immune system from attacking cells that produce insulin, which may help insulin production in patients with recently diagnosed type 1 diabetes.
To pre-qualify for this study, you must:
- Be 18 to 30 years of age
- Have been diagnosed with type 1 diabetes in the last 6 months
- Have an insulin requirement
To find out more contact us
Read about other studies we are supporting.